Piper Sandler Maintains Overweight on Indivior, Lowers Price Target to $13
Indivior Analyst Ratings
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $13
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Keeps Their Buy Rating on Indivior (INDV)
Jefferies Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $12.35
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating, Announces Target Price $15
Analysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Indivior (GB:INDV)
Stifel Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $13.9
Craig-Hallum Initiates Indivior(INDV.US) With Buy Rating
Northland Securities Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $16
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating
Indivior (INDV) Receives a Buy From Craig-Hallum
Piper Sandler Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $16
Rodman & Renshaw Initiates Indivior(INDV.US) With Buy Rating, Announces Target Price $16
Indivior Initiated With a Buy at Rodman & Renshaw
Jefferies Maintains Indivior(INDV.US) With Buy Rating, Cuts Target Price to $15.16
Jefferies Maintains Indivior(INDV.US) With Buy Rating, Maintains Target Price $24.41
Craig-Hallum Maintains Indivior(INDV.US) With Buy Rating